Quality-adjusted life year (QALY)

A health outcome measure that adjusts years of life subsequent to an intervention by the quality of life during those years

Quizartinib (Vanflyta®). HTA ID: 24006

Assessment Status Rapid Review Complete
HTA ID 24006
Drug Quizartinib
Brand Vanflyta®
Indication Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia that is FLT3-ITD positive.
Assessment Process
Rapid review commissioned 09/02/2024
Rapid review completed 11/03/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of quizartinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.